Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Date

Click to order products descending

Display 15 Products per page

Stivarga
Read More
Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently in development for the treatment of hepatocellular carcinoma (HCC).
September 9, 2019
Find out more
Nexavar
Read More
Nexavar (sorafenib; Bayer/Amgen) is a small molecule inhibitor that is currently the only targeted treatment available for first-line hepatocellular carcinoma patients.
September 9, 2019
Find out more
Bexsero
Read More
Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU. Bexsero contains three surface-exposed recombinant proteins: factor H binding protein, Neisseria adhesin A, and Neisseria heparin-binding antigen. It also includes New Zealand strain outer membrane vesicles. The antibodies generated after immunization with Bexsero target the aforementioned surface proteins present on the outer membrane vesicles.
September 3, 2019
Find out more
Menveo
Read More
Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the diphtheria toxin, as well as an aluminum phosphate adjuvant. It is approved for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals aged two months to 55 years in both the US and EU.
September 3, 2019
Find out more
MenABCW-135Y
Read More
GlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials now complete, Datamonitor Healthcare expects that Phase III trials could start by the end of 2019, and forecasts US and EU approvals in adolescents and adults to occur as early as 2022.
September 3, 2019
Find out more
Menactra
Read More
Menactra (quadrivalent polysaccharide diphtheria toxoid conjugate vaccine; Sanofi) is a quadrivalent polysaccharide diphtheria toxoid conjugate vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals aged nine months through to 55 years in the US.
September 3, 2019
Find out more
MenQuadfi
Read More
Sanofi’s MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein.
September 3, 2019
Find out more
Trumenba
Read More
Trumenba (Pfizer) is a bivalent recombinant meningococcal serogroup B vaccine indicated for immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals aged 10−25 years in the US. Trumenba is a sterile suspension composed of two recombinant lapidated factor H binding protein variants. Factor H binding protein is found on the surface of meningococci and enhances the bacterium’s ability to avoid host defense.
September 3, 2019
Find out more
Nimenrix
Read More
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
September 3, 2019
Find out more
Delstrigo
Read More
Delstrigo ([doravirine + lamivudine + tenofovir disoproxil fumarate (TDF)]; Merck & Co) is a single-tablet regimen being developed for the treatment of HIV-1 infection. The drug is a co-formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine and the two nucleos(t)ide reverse transcriptase inhibitors (NRTIs), lamivudine and TDF.
July 28, 2019
Find out more
Descovy
Read More
Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco) is a fixed-dose combination of two of Gilead’s nucleos(t)ide reverse transcriptase inhibitors, Emtriva (emtricitabine) and Vemlidy (tenofovir alafenamide [TAF]). The combination is currently approved in the US, Japan, and EU.
July 28, 2019
Find out more
Trogarzo
Read More
Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding one of the domains of the CD-4 protein, which inhibits a conformational change in CD-4 that is necessary to allow entry of HIV into T-cells.
July 28, 2019
Find out more
Cilofexor
Read More
Cilofexor (Gilead), a nonsteroidal FXR agonist, is a ligand-activated nuclear hormone receptor that is a key regulator of bile acid synthesis, conjugation, and excretion. It is abundant in the liver, gallbladder, intestines, and kidney. Stimulation of FXR in the intestine by bile acids or an FXR agonist results in the release of fibroblast growth factor 19 (FGF19).
July 22, 2019
Find out more
Cenicriviroc
Read More
Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis (NASH), and by inhibiting CCR-2/5 it is anticipated that cenicriviroc will reduce inflammation and fibrosis.
July 22, 2019
Find out more
VK2809
Read More
VK2809 (Viking Therapeutics) is a thyroid hormone receptor (THR) β-selective agonist which is selective to liver tissue. It is delivered as a prodrug. VK2809 selectively activates the cytochrome P450 isozyme 3A4 (CYP3A4), which is predominantly found in the liver. This allows increased hepatic exposure, which simultaneously reduces systemic exposure to other tissues such as skeletal muscle and the heart.
July 22, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *